Data Analysis for Promonitor® Kits
Use the free online MyAssays service to transform your Promonitor® measurement data to meaningful results in record time.
There is no complicated software to install, learn or configure. Simply provide your raw data and parameters into the kit page and your results are calculated automatically. Your tailored report is available immediately through your web browser.
Optional Premium tools are available to work within Microsoft Excel using the MyAssays Add-In, or with MyAssays Desktop to work privately on your own system keeping all of your data in-house..
Register now to process measurement data for these kits:
Promonitor® Kits
Monitoring Biological Drugs
Chronic inflammatory diseases are highly heterogeneous conditions characterized
by over production of cytokines, essential components in a body's immune response,
that when disregulated play a critical role in the pathogenesis of these diseases.
Among the cytokines tumor necrosis factor alpha (TNFα) is a key trigger in
the induction of the inflammatory cascade and therefore of disease symptoms.
The new generations of biological anti-TNFα drugs are recombinant antibody
molecules that target TNFα thereby limiting the extent to which the inflammatory
cascade is triggered.
Therapies based on this
novel class of biological drugs have provided a much-needed
alternative to clinicians for the treatment of chronic inflammatory diseases
such as rheumatoid arthritis and inflammatory bowel disease (Crohn's disease and
ulcerative colitis). Despite the widespread success of these drugs however some
patients do not respond satisfactorily or show a diminished response after prolonged
drug treatment. The failure to respond to these treatments is primarily due to the
immunogenicity of the drugs themselves, that is, the patient creates antibodies
that target the drug itself thus neutralizing the beneficial effect of treatment
and potentially even triggering an adverse drug response.
Objective Selection of Therapy and Dosage
Administration of biologic drugs should always be performed in parallel with the
close monitoring of the patient response
to the drug in order to evaluate
the efficacy of treatment and if necessary to adjust dosage or switch therapy.
Currently the assessment of patient response to the treatment of autoimmune and
inflammatory diseases is based on patient reporting of symptom severity. While such
measures are useful in assessing the impact of treatment on a patient’s quality
of life this approach fails to provide an objective biological insight into the
efficacy of treatment. The use of PROMONITOR® allows individualized optimization
of treatment regimes, thereby increasing the clinical benefit to patients and avoiding
the waste of time, money and opportunity spent on ineffective treatments. The goal
of objectively measuring drug response is achieved by PROMONITOR® through the
measurement of both drug bioavailability and immunogenicity.
Promonitor® is a product developed by Proteomika and distributed worldwide. Please contact your local distributor to place an order.